

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/568,301
		Filing Date	January 26, 2007
		First Named Inventor	Fu-Yue Zeng
		Group Art Unit	3381
		Examiner Name	unknown
Sheet 1 of 1	Attorney Docket Number	AREN-0065	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1					
	A2					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴ (if known)				
	B1						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	SEXTON et al., "Receptor activity modifying proteins," Cellular Signalling (2001) 13:73-83	
	C2	RIOS et al., "G-protein-coupled receptor dimerization: modulation of receptor function," Pharmacology & Therapeutics (2001) 92:71-87	
	C3	ANGERS et al., "DIMERIZATION: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function," Annual Review of Pharmacology and Toxicology (2002) 42:409-435	
	C4	ANGNATI et al., "Molecular Mechanisms and Therapeutic Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons," Pharmacological Reviews (2003) 55:509-550	
	C5	JOOST et al., "Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands," Genome Biology (2002) 3(11):research0063.1-0063.16:1-16	
	C6	MCVEY et al., "Monitoring Receptor Oligomerization Using Time-resolved Fluorescence Resonance Energy Transfer and Bioluminescence Resonance Energy Transfer," The Journal of Biological Chemistry (2001) 276:14092-14099	
	C7	HILAIRET et al., "Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor," The Journal of Biological Chemistry (2003) 278:23731-23737	
	C8	XU et al., "Heterodimerization of α_A and β_1 - Adrenergic Receptors," The Journal of Biological Chemistry (2003) 278:10770-10777	
	C9	FLOYD et al., "CSa Receptor Oligomerization," The Journal of Biological Chemistry (2003) 278:35354-35361	
	C10	KLCO et al., "CSa Receptor Oligomerization," The Journal of Biological Chemistry (2003) 278:35345-35353	
	C11		

Examiner Signature	/Michael Pak/	Date Considered	12/19/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kind of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.